Author

Adam Gregory

Observed names: Adam P. Gregory, Gregory, A, Gregory, Adam P.

Institutions: MRC Clinical Trials Unit at UCL, University College London

Observed institutions: John Radcliffe Hospital, University of Oxford, MRC Clinical Trials Unit at UCL, MRC Weatherall Institute of Molecular Medicine, MRC Human Immunology Unit, University College London, Medical Research Council

OpenAlex ID: A5068237677

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

2012 · Adam P. Gregory, Calliope A. Dendrou, et al. · Nature · 384

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

2021 · Wesley H. Self, Uriel Sandkovsky, et al. · The Lancet Infectious Diseases · 190

PDF

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

2020 · Sarah Fidler, Wolfgang Stöhr, et al. · The Lancet · 136

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels

2021 · ACTIV-3/TICO Bamlanivimab Study Group*, Jens D. Lundgren, et al. · Annals of Internal Medicine · 77

PDF

The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19

2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60

PDF

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

2022 · ACTIV-3/TICO Study Group*, Christina Barkauskas, et al. · Annals of Internal Medicine · 31

PDF

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

2025 · Silke Gillessen, Silke Gillessen, et al. · The Lancet Oncology · 26

PDF

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19

2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 15

PDF

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV

2024 · Leanne McCabe, James E. Burns, et al. · AIDS · 6

Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

2024 · Tomas O Jensen, Thomas A Murray, et al. · The Lancet Microbe · 6

MRC SORCE trial: Analysis of patients' presenting characteristics, tumor staging, and surgical approach.

2014 · Alastair W. S. Ritchie, Angela M. Meade, et al. · Journal of Clinical Oncology · 6

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

2020 · Hongbing Yang, Anuska Llano, et al. · Cell Reports · 5

PDF

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

2023 · Tomas O Jensen, Greg A Grandits, et al. · The Journal of Infectious Diseases · 4

PDF

SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)

2025 · Sofía Sábato, Susana Benet, et al. · Scientific Reports

Maraviroc with or Without Metformin for the Treatment of Non-Alcoholic Fatty Liver Disease in Virologically Suppressed Adults with HIV (MAVMET)

2023 · Leanne McCabe, James E. Burns, et al. · SSRN Electronic Journal

Nature

2012 · Gregory, A., Dendrou, C., et al. · MPG.PuRe (Max Planck Society)

Functional characterisation of a multiple sclerosis-associated genetic variant

2012 · Gregory, Adam P. · OpenGrey (Institut de l'Information Scientifique et Technique)

Works count: 11

Citation count: 581

H-index: 5

I10-index: 4